The EU AI Act is no longer on the horizon—it’s here. In August 2026, the core requirements for high-risk AI systems become fully applicable, and AI-enabled medical devices sit squarely at the center of this regulatory shift. For manufacturers and healthcare organizations developing these systems, the window for preparation is closing fast.
But the AI Act doesn’t exist in a vacuum. It converges with existing medical device regulations and emerging AI governance standards, creating a layered compliance landscape that demands a new, integrated approach to development and lifecycle management.
Understanding what’s coming—and acting now—is the difference between scrambling for compliance and turning it into a strategic advantage.
What Changes in August 2026
The EU AI Act classifies AI-enabled medical devices as high-risk AI systems. Starting in August 2026, these systems will be subject to stringent obligations that go well beyond what most manufacturers have dealt with under existing frameworks:
- Risk Classification: AI systems must be assessed and classified according to the risk they pose, with medical devices facing some of the strictest requirements.
- Bias Mitigation: Developers must demonstrate that training data and model outputs are monitored and controlled for bias—particularly critical in healthcare, where biased AI can directly impact patient safety.
- Transparency: Users and affected individuals must be informed when AI is involved in decision-making, including clear documentation of system behavior and limitations.
- Post-Market Monitoring: Ongoing surveillance of AI system performance is now mandatory, ensuring that deployed models continue to meet safety and effectiveness standards over time.
These are not aspirational guidelines. They are enforceable requirements with real consequences for non-compliance, including significant fines and market access restrictions.
A Converging Regulatory Landscape
For medical device manufacturers, the AI Act doesn’t replace existing obligations—it adds to them. Compliance will increasingly require alignment across three distinct but overlapping frameworks:
Product Regulation: EU MDR and ISO 13485
The EU Medical Device Regulation (MDR) and ISO 13485 remain the foundation. They ensure that the device is safe and effective, that clinical evaluation is rigorous, and that development follows controlled lifecycle management processes. These frameworks are well-established, and most manufacturers already operate within them.
AI Governance: ISO/IEC 42001 and the EU AI Act
ISO/IEC 42001 provides a structured approach to governing AI systems, covering risk management, data governance, and continuous monitoring. The EU AI Act introduces horizontal regulatory obligations specific to AI risks and system behavior. Together, they ensure that AI is not only functional but trustworthy, transparent, and accountable.
The Layered Compliance Model
What emerges is a three-layer model that organizations must operationalize:
- Product regulation (MDR) ensures the device is safe and effective.
- Quality system (ISO 13485) ensures controlled development and lifecycle management.
- AI governance (ISO/IEC 42001 + AI Act) ensures trustworthy, transparent, and monitored AI behavior.
Each layer serves a distinct purpose, but none can function effectively in isolation. The key challenge is no longer understanding each framework individually—it is operationalizing them together within a single, coherent lifecycle.
What Organizations Should Be Doing Right Now
Waiting for final guidance or delegated acts is no longer a viable strategy. Organizations developing AI-based medical devices should already be taking concrete steps:
- Integrating AI risk management into their QMS: AI-specific risks—model drift, data quality issues, algorithmic bias—must be captured within existing quality management processes, not treated as separate concerns.
- Aligning post-market surveillance with AI monitoring requirements: Traditional vigilance and post-market surveillance need to expand to include continuous monitoring of AI system performance, fairness, and reliability.
- Strengthening data governance and bias controls: The quality, representativeness, and traceability of training data must meet both MDR expectations for clinical evidence and AI Act requirements for bias mitigation.
- Preparing for conformity assessments under both MDR and AI Act frameworks: Dual conformity paths are becoming a reality. Understanding how notified bodies will assess AI-specific requirements alongside device safety is essential for a smooth approval process.
Early assessment of impacts across the development lifecycle—particularly in risk management, data governance, and conformity assessment—is not just prudent. It is the most effective way to avoid significant compliance gaps when August arrives.
How Daiki Supports Your AI Act Readiness
Navigating a multi-framework compliance landscape is complex, but it doesn’t have to be chaotic. The Daiki AI Management System (AIMS) is designed to help organizations build and maintain the governance structures that regulators now expect:
- Integrated Risk Management: AIMS helps map AI-specific risks alongside existing QMS processes, ensuring nothing falls through the cracks between MDR and AI Act obligations.
- Data Governance and Bias Monitoring: The platform supports structured data governance workflows, helping teams document data provenance, assess representativeness, and track bias controls throughout the AI lifecycle.
- Compliance Tracking: AIMS provides clear visibility into your organization’s readiness across multiple frameworks, making it straightforward to identify gaps and demonstrate conformity to auditors and notified bodies.
- Continuous Monitoring: Built-in monitoring capabilities support the post-market surveillance obligations that both MDR and the AI Act demand for high-risk systems.
By bringing these capabilities together in a single platform, Daiki enables organizations to move from fragmented compliance efforts to a coherent, auditable governance model.
Compliance as Competitive Advantage
The organizations that will lead in AI-enabled healthcare are not those that treat regulation as a checkbox exercise. They are the ones that recognize governance as a foundation for trust—trust from patients, clinicians, regulators, and partners.
The EU AI Act raises the bar, but it also clarifies expectations. For those who start early, it creates an opportunity to differentiate: demonstrating not just that your AI works, but that it works responsibly, transparently, and within a framework designed to keep it that way.
Those who act now will turn compliance into a competitive advantage. Those who wait may find themselves playing catch-up in a market that has already moved on.
